Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front Immunol. 2020;11: 574271.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.

Article  CAS  PubMed  Google Scholar 

Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022;22(1): e2.

Article  PubMed  PubMed Central  Google Scholar 

FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma: U.S. Food & Drug Administration; [Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel.

Keam SJ. Tremelimumab: first approval. Drugs. 2023;83(1):93–102.

Article  CAS  PubMed  Google Scholar 

FDA approves Opdualag for unresectable or metastatic melanoma: U.S. Food and Drug Administration; [Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdualag-unresectable-or-metastatic-melanoma#:~:text=On%20March%2018%2C%202022%2C%20the,with%20unresectable%20or%20metastatic%20melanoma.

Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018;320(16):1702–3.

Article  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

Article  CAS  PubMed  Google Scholar 

Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563–72.

Article  CAS  PubMed  Google Scholar 

Bui AN, Hirner J, Singer SB, Eberly-Puleo A, Larocca C, Lian CG, et al. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol. 2021;46(2):328–37.

Article  CAS  PubMed  Google Scholar 

Said JT, Elman SA, Perez-Chada LM, Mita C, Merola JF, LeBoeuf NR. Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review. J Am Acad Dermatol. 2022;87(2):399–400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen N, Wan G, Ugwu-Dike P, Alexander NA, Raval N, Zhang S, et al. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. J Am Acad Dermatol. 2023.

Placais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, et al. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. Ann Rheum Dis. 2022;81(10):1445–52.

Article  CAS  PubMed  Google Scholar 

Bender DA, Heilbroner SP, Wang TJC, Shu CA, Hyde B, Spina C, et al. Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease. J Immunother Cancer. 2020;8(2): e001627.

Article  PubMed  PubMed Central  Google Scholar 

Nice L, Bycroft R, Wu X, Rai SN, Figg L, Bhandari S, et al. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors. J Oncol Pharm Pract. 2021;27(7):1736–42.

Article  CAS  PubMed  Google Scholar 

Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, et al. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. 2021;9(3): e001935.

Article  PubMed  PubMed Central  Google Scholar 

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–8.

Article  PubMed  Google Scholar 

Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021;85(4):956–66.

Article  CAS  PubMed  Google Scholar 

Fatima S, Veenstra J, Antonyan AS, Kohen L. Severe recalcitrant morbilliform eruption from dual immune checkpoint blockade. JAAD Case Rep. 2018;4(6):593–5.

Article  PubMed  PubMed Central  Google Scholar 

Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158–76.

Article  PubMed  Google Scholar 

Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.

Article  CAS  PubMed  Google Scholar 

Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:76–83.

Article  Google Scholar 

Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gutzmer R, Wollenberg A, Ugurel S, Homey B, Ganser A, Kapp A. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int. 2012;109(8):133–40.

PubMed  PubMed Central  Google Scholar 

Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin Dermatol. 2020;38(1):94–104.

Article  PubMed  Google Scholar 

Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–8.

Article  CAS  PubMed  Google Scholar 

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264-iv6.

Patel AB, Pacha O. Skin reactions to immune checkpoint inhibitors. Adv Exp Med Biol. 2018;995:117–29.

Article  PubMed  Google Scholar 

Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous Immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management [formula: see text]. J Cutan Med Surg. 2021;25(1):59–76.

Article  CAS  PubMed  Google Scholar 

Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990–7.

Article  CAS  PubMed  Google Scholar 

Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–61 e1.

Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128–36.

Article  PubMed  PubMed Central  Google Scholar 

Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol. 2017;39(2):121–9.

Article  PubMed  Google Scholar 

Guggina LM, Yanes DA, Choi JN. Inverse lichenoid drug eruption associated with nivolumab. JAAD Case Rep. 2017;3(1):7–9.

Article  PubMed  Google Scholar 

Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol. 2017;31(10):e464–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strickley JD, Vence LM, Burton SK, Callen JP. Nivolumab-induced lichen planus pemphigoides. Cutis. 2019;103(4):224–6.

PubMed  Google Scholar 

Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339–46.

Article  PubMed